Partnering With Kite Pharma to Bring CAR T-Cell Therapy Closer to Patients – BBG Advanced Therapies
BBG Advanced Therapies shared a post on LinkedIn: “We’re proud to announce a collaboration between BBG Advanced Therapies and Kite Pharma, a Gilead Company, on an initiative designed to expand access…
Read the full articleYou might also wanna read
CancerNetwork: Illuminating Optimal CAR T-Cell Therapies Across Large B-Cell Lymphoma Groups
The post CancerNetwork: Illuminating Optimal CAR T-Cell Therapies Across Large B-Cell Lymphoma Groups appeared first on UNC Lineberger Compr
CGT Catapult teams with Korecyte Bio on low-oxygen detecting CAR-T program
A startup biotech company out of King’s College London is using hypoxia to target solid tumors.
OHSU logra un gran avance en la ciencia médica con las terapias celulares
Los pacientes se benefician de la terapia CAR-T para tratar enfermedades neurodegenerativas, cáncer, lupus y otras afecciones autoinmunes.
Cette thérapie permet de transformer les cellules immunitaires en arme contre le cancer grâce à une injection chez la souris
Une avancée majeure en thérapie génique permet de reprogrammer les cellules immunitaires directement dans le corps pour cibler les tumeurs,
Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease
Conditions : Advanced Solid Tumor Cancer; Triple-Negative Breast Cancer (TNBC); CNS Disease; Breast Cancer Interventions : Drug: Tislelizuma
AI-guided discovery identifies GPNMB as promising CAR T cell target for multiple cancers
An AI-guided framework integrating high-resolution cellular atlases, public knowledge databases, and large language models enables a modular
Comments
Sign in to join the conversation.
No comments yet. Be the first.